Table 3.
ORs for the risk of ACS by quartiles of Hsp70 and anti-Hsp70 antibody levels
| Quartile | P trend | ||||
|---|---|---|---|---|---|
| 1st | 2nd | 3rd | 4th | ||
| Hsp70 | |||||
| Range, ng/mL | <0.91 | ≥0.91 to <2.36 | ≥0.91 to < 4.39 | ≥4.39 | |
| Control/ACS | 120/56 | 126/51 | 95/83 | 76/101 | |
| Crude (95% CI) | 1.00 | 0.87 (0.55-1.37) | 1.87 (1.21-2.89) | 2.85 (1.84-4.40) | <0.0001 |
| Adjusted ORa (95% CI) | 1.00 | 0.75 (0.44-1.28) | 1.66 (1.00-2.73) | 2.61 (1.57-4.33) | <0.0001 |
| Anti-Hsp70 antibody | |||||
| Range, µg/mL | <200.21 | ≥200.21 to <275.26 | ≥275.26 to < 413.24 | ≥413.24 | |
| Control/ACS | 85/92 | 99/78 | 119/58 | 114/63 | |
| Crude (95% CI) | 1.00 | 0.73 (0.48-1.11) | 0.45 (0.29-0.69) | 0.51 (0.33-0.78) | 0.0003 |
| Adjusted ORa (95% CI) | 1.00 | 0.67 (0.41-1.09) | 0.36 (0.21-0.59) | 0.46 (0.28-0.76) | 0.0003 |
aAdjusted for age, sex, smoking, BMI, hypercholesterolemia, hypertension, diabetes, and family history of CHD